ScholarIQanswers from OpenAlex & ORCID
Richard M. Goldberg
ResearcherPublications, citations & collaboration network
Richard M. Goldberg is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard M. Goldberg have?
ScholarIQindexed works
Richard M. Goldberg has 1,026 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard M. Goldberg have?
ScholarIQcitation count
Richard M. Goldberg has 66,145 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard M. Goldberg?
ScholarIQh-index
Richard M. Goldberg has an h-index of 107 in OpenAlex.
What is the i10-index of Richard M. Goldberg?
ScholarIQi10-index
Richard M. Goldberg has an i10-index of 383 in OpenAlex.
What is the ORCID of Richard M. Goldberg?
ScholarIQorcid
The ORCID for Richard M. Goldberg is on the source record.
What is the OpenAlex record for Richard M. Goldberg?
ScholarIQopenalex
The OpenAlex for Richard M. Goldberg is on the source record.
What are the most-cited papers on Richard M. Goldberg?
ScholarIQmost cited works
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra Eyring, Andrew D. Skora, Brandon Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Díaz
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne R. Bartlett, Laveet K. Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon Luber, Fay Wong, Nilofer S. Azad, Agnieszka A. Rucki, Dan Laheru, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Tim F. Greten, Austin G. Duffy, Kristen K. Ciombor, Aleksandra Eyring, Bao H. Lam, Andrew K. Joe, Soonmo Peter Kang, Matthias Holdhoff, Ludmila Danilova, Leslie Cope, Christian F. Meyer, Shibin Zhou, Richard M. Goldberg, Deborah K. Armstrong, Katherine M. Bever, Amanda N. Fader, Janis M. Taube, Franck Housseau, David Spetzler, Nianqing Xiao, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, James R. Eshleman, Bert Vogelstein, Robert A. Anders, Luis A. Díaz
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
Joel E. Tepper, Mark J. Krasna, Donna Niedzwiecki, Donna Hollis, Carolyn E. Reed, Richard M. Goldberg, Krystyna Kiel, Christopher G. Willett, David J. Sugarbaker, Robert J. Mayer
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert I. Hurwitz, Federico Innocenti, Mary F. Mulcahy, Eileen M. O’Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg